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imaging novelty responses to scene images.
Results: Total tau levels were specifically and negatively associated with novelty responses in the
right amygdala and right hippocampus. Mediation analyses showed no evidence that these associa-
tions were dependent on the volume of hippocampus/amygdala. No relationship was found between
phosphorylated-tau or Ab42 levels and novelty responses.
Discussion: Our data show that CSF levels of total tau are associated with anatomically specific re-
ductions in novelty processing, which cannot be fully explained by atrophy.
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The hallmarks of Alzheimer’s disease (AD) pathology
are extracellular amyloid aggregates and intracellular accu-
mulation of hyperphosphorylated tau [1,2]. In the
cerebrospinal fluid (CSF), increasing levels of total tau and
phospho tau (p-tau) and decreasing levels of Ab42 provide
indirect measures of the magnitude of these pathologies
[3,4–8]. Although it is well established that amyloid
pathology can be associated with synaptic dysfunction [2],
tau pathology is widely considered to reflect neurodegener-
ation [9–12]. According to this view, CSFAb42 levels should
be associated with synaptic dysfunction [13] potentially irre-
spective of atrophy, whereas any relationship between CSF
levels of total tau and synaptic function should depend on
neuronal damage, potentially indexed by the volume of the
underlying brain region. In the recent NIA-AA research
framework [12], models hypothesized to explain cognitive
dysfunction as a result of biomarker-related pathology all
postulate neurodegeneration as a mediator. However, more
recent discussions consider the possibility that tau can also
be associated with synaptic dysfunction before neurodegen-
eration has occurred [14].
We first investigated in which brain regions the magni-
tude of the functional magnetic resonance imaging (fMRI)
novelty response for scenes [15] was independently associ-
ated with CSF levels of tau and amyloid. We used an unbi-
ased approach considering whole-brain novelty responses,
unlike recent studies that focused on the hippocampus and
the medial temporal lobe [16]. We then determined whether
any association was dependent on the local volume of the
underlying region, which we considered a surrogate for
structural integrity, hence neurodegeneration.2. Methods
2.1. Overall study design
The DZNE-Longitudinal Cognitive Impairment and De-
mentia Study (DELCODE) is an observational longitudinal
memory clinic-based multicenter (10 sites) study of the
German Center for Neurodegenerative Diseases (DZNE)in Germany. The detailed study design of DELCODE is
reported in the study by Jessen et al. [17]. The participants
to be enrolled are 400 subjects with subjective cognitive
decline (SCD), 200 patients with mild cognitive impairment
(MCI), 100 patients with Alzheimer’s dementia, 200 control
subjects without subjective or objective cognitive decline,
and 100 first-degree relatives of patients with a documented
diagnosis of Alzheimer’s dementia. All patient groups
(SCD, MCI, AD) are referrals, including self-referrals while
the control group and the relatives of Alzheimer’s dementia
patients are recruited by standardized public advertisement.
The current analysis is based on the first 400 participants of
the still ongoing baseline recruitment.
All local institutional review boards and ethical commit-
tees approved the study protocol. All participants gave writ-
ten informed consent before inclusion in the study.
DELCODE is retrospectively registered at the German Clin-
ical Trials Register (DRKS00007966), (04/05/2015). Data
handling and quality control are reported in the study by Jes-
sen et al. [17].
2.2. Participants
SCD was defined by the presence of subjectively reported
decline in cognitive functioning and a test performance above
21.5 standard deviations below the age-, sex-, and education-
adjusted normal performance on all subtests of the CERAD
(Consortium to Establish a Registry of Alzheimer’s Disease)
test battery [18]. MCI (amnestic) was defined by an age-, sex-
and education-adjusted performancebelow21.5 standard de-
viations on the delayed recall trial of the CERAD word-list
episodic memory tests. Both patient groups (SCD and MCI)
fulfilled the current research criteria for SCD [18] or MCI
[9], respectively. Mild Alzheimer’s dementia [19] included
a lower cutoff on the Mini–Mental State Examination of
18 points. Additional inclusion criteria for all groups were
aged 60 years, fluent German language skills, capacity to
provide informed consent, and presence of a study partner.
For exclusion criteria, see the study by Jessen et al. [17].Other
neuropsychological assessments included ADAS-cog 13,
FCSRT-IR,WMS-RLogicalMemory StoryA,WMS-RDigit
Span, semantic fluency (animals), the oral form of the
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Clock Drawing, and Clock Copying [17].
2.3. CSFAD biomarker assessment
CSF AD biomarkers were determined centrally at the
Bonn site using commercially available kits according to
vendor specifications (V-PLEX Ab Peptide Panel 1 (6E10)
Kit, K15200E and V-PLEX Human Total tau Kit,
K151LAE; Meso Scale Diagnostics LLC, Rockville, USA;
and Innotest Phospho-Tau(181P), 81581; Fujirebio
Germany GmbH, Hannover, Germany) [17].
2.4. MRI acquisition
MRI data were acquired at nine scanning sites, all with
Siemens scanners (3 TIM Trio systems, 4 Verio systems,
one Skyra, and one Prisma system). For the current report,
T1- (3D GRAPPA PAT 2, 1 mm3 isotropic, 256 ! 256 px,
192 slices, sagittal, w5 min, TR 2500 ms, TE 4.33 ms, TI
110 ms, FA 7) and T2-weighted (optimized for medial tem-
poral lobe volumetry, 0.5! 0.5! 1.5 mm3, 384! 384 px,
64 slices, orthogonal to the hippocampal long axis,w12 min,
TR 3500 ms, TE 353 ms) images and a task-fMRI protocol
(2D EPI, GRAPPA PAT 2, 3.5 mm3 isotropic, 64 ! 64 px,
47 slices, oblique axial/AC-PC aligned, w9 min, TR
2580 ms, TE 30 ms, FA 80, 206 volumes) were used.
For task fMRI, all sites used the same 3000 MR-compatible
LCD screen (Medres Optostim) matched for distance, lumi-
nance, color and contrast constant across sites, and the same
response buttons (CurrentDesign). All participants underwent
vision correctionwithMR-compatible goggles (MediGlasses,
Cambridge Research Systems) according to the same stan-
dard operating procedures. Standard operating procedures
and quality assurance and assessment (QA) were provided
and supervised by the DZNE imaging network (iNET, Mag-
deburg) as described in the study by Jessen et al. [17].
2.5. Task fMRI
During the fMRI session, subjects performed a modified
version of a previously published scene novelty and encoding
task (“FADE”) [15]. Here, 44 were novel indoor scenes, 44
were novel outdoor scenes, and 44were repetitions of the pre-
familiarized images (one indoor and one outdoor, 22 times
each; all 8-bit gray scale, scaled to 1250! 750 pixel resolu-
tion and matched for luminance, viewing horizontal half-
angle was 10.05) were presented (Neurobehavioral Systems
Inc.), and subjects had to classify them as either “indoor” or
“outdoor” by button press. Stimuli were shown for 2500 ms
each, with an optimized jitter for statistical efficiency [20].
206 functional volumes were recorded with a TR of 2.58 s.
The whole task took around 11 minutes. Following a delay
of 70 min, recognition memory for the novel 88 images was
tested together with 44 entirely new images (22 indoor, 22
outdoor) outside of the MRI scanner (viewing horizontal
half-angle was 10.05). Recognition memory responseswere given on a 5-step scale (1: “I am sure that this picture
is new”/2: “I think that this picture is new”/3: “I cannot decide
if this picture is new or old”/4: “I think I saw this picture
before”/5: “I am sure that I did see this image before”).
2.6. MRI analysis2.6.1. Single subject analyses
After preprocessing (slice time correction, unwarping,
realignment, and spatial smoothing [isotropic gaussian
kernel of FWHM 6! 6! 6 mm]; SPM, version 12; Well-
come Trust Centre for Neuroimaging, London, UK), first-
level general linear models were calculated in native space
(including 6motion regressors from the realignment process)
using a hemodynamic response function with a 128-second
high-pass filter, no global scaling, and no serial correlations
were modeled. Prefamiliarized and novel stimuli were used
to calculate a “novelty” contrast (“novel vs. old images”).
2.6.2. Group-level analyses
A study-specific group template was calculated using the
RF-bias-corrected (N4-ITK [21]) MPRAGE images using
ANTs v2.1 [22]. Four rigid-then-affine iterations were fol-
lowed by six full runs of a nonlinear multi-resolution routine
to ensure stable convergence (three resolutions, maximum of
90 iterations, template update step size of 0.1 mm). The re-
sulting SPM contrast images for the “novelty” contrast were
warped to the study-specific group template. Co-registration
parameters (Mean EPI to MPRAGE) and spatial normaliza-
tion parameters resulting from the template creation were
applied to individual contrast images using ANTs. The
normalized contrast images were entered into planned mul-
tiple regression analyses as outlined below.
2.6.3. Cortical volume analysis
FreeSurfer 6.0 (http://surfer.nmr.mgh.harvard.edu/) was
used to calculate measures for cortical volume and hippo-
campal segmentations by combining T1- and T2-weighted
images using a multispectral analysis algorithm [23].2.7. Statistical analyses
Behavioral data were analyzed using SPSS 23 (IBM, Ar-
monk, USA). Regression analyses with the fMRI novelty
contrast (blood oxygenation level dependent activity difference
between novel and repeated scenes) followed a whole-brain
approach andwere done using SPM12 (WellcomeTrust Centre
for Neuroimaging, London, UK) applying family-wise error
rate cluster-level correction formultiple comparisons. To assess
the specific effects of CSF total tau, phospho tau, or amyloid on
whole-brain novelty responses, three main models were set up.
1. CSF total tau as a regressor using the MRI site, age,
gender, and Ab42 levels as covariates.
2. CSF p-tau as a regressor using the MRI site, age,
gender, and Ab42 levels as covariates.
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gender, and total tau levels as covariates.
2.7.1. Mediation analyses
The influence of local brain volume on correlations be-
tween CSF biomarker levels and local novelty responses
were assessed with a mediation analyses (SPSS 24 using
the PROCESS module [24]).
2.8. Data availability
Data, study protocol, and biomaterials can be shared with
partners based on individual data and biomaterial transfer
agreements.
3. Results
3.1. Participants and demographics
Of the first 400 participants of the DELCODE study, 76
who were classified as healthy controls (HCs), SCD, or
MCI also completed task fMRI and contributed CSF
(Table 1). Among these 76 individuals, the Mini–Mental
State Examination scores were similar in HCs and SCD,
and lower in MCI than HCs (T 5 3.6, P 5 .001). CSF total
tau and p-tau values were not significantly different between
HCs and SCD but higher in MCI than in HCs (total tau:
T 5 23.3, P 5 .002; p-tau: T 5 22.5, P 5 .013). CSF
Ab42 levels were not significantly different between these
groups (P . .08).3.2. Behavioral results from the task-fMRI paradigm
Recognition memory accuracy (dprime) for novel scene
images (Table 1) was equivalent between HCs and SCD par-
ticipants. MCI participants performed significantly lower
than HCs (T 5 4.3; P 5 .000) and SCD participantsTable 1
Characteristics of participants who completed task-fMRI
Age MMSE
ADAS
delayed
recall Dprime Ab42
Total
tau
p-
tau
Healthy controls,
N 5 40
Mean 67.7 29.4 7.7 1.14 834.1 325.3 46.3
SD 5.15 0.9 1.7 0.37 295.8 113.0 15.1
SCD, N 5 21
Mean 70.0 29.0 7.7 1.09 892.0 367.1 53.6
SD 5.96 1.1 1.9 0.48 325.5 102.5 16.8
MCI, N 5 15
Mean 72.4 28.1 4.5 0.70 674.3 450.0 59.2
SD 4.88 1.6 2.4 0.39 305.0 151.7 19.6
Abbreviations: MMSE, Mini–Mental Status Examination; MCI, mild
cognitive impairment; SCD, subjective cognitive decline; fMRI, functional
magnetic resonance imaging.
NOTE. Dprime is a measure of memory discrimination of repeated scenes
(presented during task-fMRI) and new distractors (not presented during
task-fMRI). A value of 0 would correspond to chance-level performance.
Mean values are given in bold.(T 5 3.3; P 5 .001) (Table 1). Partial correlations with age
as a covariate showed a significant negative correlation be-
tween CSF total tau and dprime (R 5 20.313; P 5 .007)
(Fig. 1). Correlations between p-tau and dprimeweremargin-
ally significant (R520.226; P5 .053). There were no cor-
relations between dprime and Ab42 levels (P . .5).3.3. Functional MRI results3.3.1. Group-level novelty effect
Table 2 lists the brain regions that in a first-level contrast
showed increased blood oxygenation level dependent re-
sponses to novel as compared to familiar scenes in the entire
sample of 76 participants (family-wise error rate
cluster , 0.05). As also depicted in Fig. 2, novel images
were associated with activation of two large clusters, which
comprised the expected network of hippocampus, medial
temporal lobes, visual areas, and precuneus, as well as
medial frontal and insula.
3.3.2. CSF total tau and p-tau as regressors
Only clusters in the hippocampus and the amygdala (on
the right) showed a significant negative correlation between
novelty and total tau (FWEcluster , 0.05) (Fig. 2). Thus,
higher CSF total tau was associated with lower novelty re-
sponses. There was no significant correlation with p-tau.
3.3.3. CSFAb42 levels as a regressor
No significant correlations were found.
3.3.4. Mediation analyses with regional volumes
As shown in Fig. 3, the regression of CSF total tau on
reduced novelty activation, ignoring the combined right
hippocampal and amygdala volumes, was significantFig. 1. Correlation between CSF levels of total tau (pg/mL) and recognition
memory accuracy (dprime) for the novel scenes presented during task-
fMRI. Color codes indicate healthy controls (blue), subjective complainers
(subjective cognitive decline, green), and individuals with mild cognitive
impairment (mild cognitive impairment, orange).
Table 2
Group-level results of novelty contrast thresholded at p cluster level , .05 (N 5 76)
Cluster size Cluster pFWE Peak T Template x,y,z (mm) Brain structures contained in main cluster
47,206 0.000 17.38 28, 242, 214 L & R each: amygdala, calcarine, sup. cuneus, cerebellum, vermis, G.
fusiformis, hippocampus, lingualis, occipital, parahippocampal, parietal,
postcentral, precuneus, temporal, thalamus
R: Putamen
17.04 34, 282, 18 (submaximum of first cluster)
16.58 230, 290, 12 (submaximum of first cluster)
10,086 0.000 8.93 234, 32, 210 L & R each: Med. cingulate, Frontal (Tri., Orb., Oper.), Orb. frontal, insula,
postcentral, precentral, rectus, suppl. motor
7.78 46, 4, 28 (submaximum of second cluster)
7.69 8, 10, 48 (submaximum of second cluster)
NOTE. Structure labels in activated clusters were identified using the AAL Toolbox in SPM12. Coordinates in Table 2 are MNI space.
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combined right hippocampal and amygdala volume was also
significant [b 5 21.323, P , .05]. The regression of com-
bined right hippocampal and amygdala volume, controllingFig. 2. Novelty activations and regression analyses. (A) Group-level contrast depi
the entire sample of 76 participants (depicted at P , .001 uncorrected, k 5 400 v
depicts activation on group template (left is left). (B) Whole-brain regression anal
novelty responses in the amygdala (left panel) and the hippocampus (right panel).
ations: CSF, cerebrospinal fluid; MRI, magnetic resonance imaging.for tau pathology, on novelty activation was not significant
[b5 0.0003, P 5 .65]. When controlling for combined right
hippocampal and amygdala volumes, CSF total tau still pre-
dicted reduced novelty [b 5 20.015, P , .001]. Thecting increased BOLD responses to novel as compared to familiar scenes in
oxels). Left panel shows entire activation map as a glass brain. Right panel
ysis with CSF total tau levels. CSF total tau levels correlate selectively with
Covariates were MRI sites (6 sites), age, gender, and Ab42 levels. Abbrevi-
Fig. 3. Mediation analyses. Total tau levels have a significant association
with hippocampus 1 amygdala volume. The volume of
hippocampus1 amygdala, however, does not have a significant association
with novelty. As expected (given the selection of the novelty cluster), there
is also a significant influence on novelty responses in the hippocampus/
amygdala clusters. More importantly, the direct effect of total tau levels
on novelty responses remains significant after controlling for hippocam-
pus/amygdala volume.
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significantly different from zero, as revealed by a 95% boot-
strap confidence interval that did contain zero [confidence in-
terval: 20.0019 to 0.0011]). Thus, the combined right
hippocampal and amygdala volume did not mediate the rela-
tionship between increasedCSF levels of total tau and reduced
novelty responses in the hippocampus and amygdala.
3.3.5. Relationship between novelty responses and
recognition memory performance
To assess whether the novelty response in the hippocam-
pus/amygdala correlated with recognition memory perfor-
mance for the novel scenes, we conducted partial
correlations with the right hippocampus/amygdala novelty
responses and recognition memory dprime using age and
right hippocampus volume as covariates. This revealed a sig-
nificant correlation (R5 .244; P5 .043). The corresponding
analysis for the precuneus was not significant on either side
(P . .2).4. Discussion
The perirhinal and entorhinal cortices, hippocampus,
amygdala, precuneus, medial prefrontal, and parietal cortex
are core components of an episodic memory network that en-
ables detecting of and orienting toward novel events and their
subsequent encoding [15,25]. Indeed, fMRI studies have
consistently shown, as we have observed in this study
(Fig. 2A), that these regions are more active in response to
novel as compared to repeated/familiarized images of scenes
[15,26,27]. Given this widespread novelty network, the
regional specificity of the correlations between CSF
total tau levels and neural novelty responses in the
hippocampus/amygdala is striking (Fig. 2B).With increasing
levels of total tau, hippocampal/amygdala novelty responses
and recognition memory accuracy decreased. This finding
suggests that there is a linearly increasing impact of tau
pathology on hippocampal and amygdala function across
HCs and individuals with MCI.Neural activation to novel stimuli is a hallmark process of
forming new episodic memories [15,28]. Although a number
of previous studies have investigated the relationship
between whole-brain resting-state activity and CSF bio-
markers (i.e., [29]), very few studies have considered task-
related whole-brain activity. Our results reveal a converging
relationship between a functional reduction in novelty re-
sponses and a reduction in the ability to behaviorally recog-
nize those novel images after a long delay of ca 70 minutes;
both measures were related to the same biomarker and were
also correlated with each other independent of hippocampal
volume. This convergence indicates that the reductions of
novelty responses were indeed behaviorally relevant for
forming a memory for the novel scenes.
In the recent NIA-AA research framework [12], models
hypothesized to explain cognitive dysfunction because of
biomarker-related pathology all postulate neurodegenera-
tion as a mediator. Although total tau levels also showed
an association with hippocampal/amygdala volumes in our
study, the relationship with novelty remained independent
of volume (Fig. 3). Hippocampal volume is considered to
be an important biomarker for AD and is correlated with a
number of medial temporal lobe dependent cognitive func-
tions [30]. CSF tau levels have been associated with neuro-
degeneration because the release of full-length tau into the
CSF has been postulated to be a result of neuronal death
[12]. However, a recent study showed that CSF levels of
tau also include truncated tau, which can be released into
the CSF from intact neurons [31]. Our data suggest an
atrophy-independent functional impact of tau pathology on
hippocampal memory encoding, which may be mediated
by such tau species from intact neurons and which may
even be reversible within the preclinical spectrum of AD.
This has implications for future tau-based therapies.
The structure-independent functional impact of tau
pathology that we observed here is consistent with animal
studies showing that misfolded and hyperphosphorylated tau
can impair neuronal function [14,32]. Early local
accumulations of pathological tau in axons lead to presynaptic
dysfunction, neuronal hypoactivity, and strong behavioral
deficits in mice, and this effect can be rectified by restoring
neuronal energy balance [33]. Mislocation of tau to dendritic
spinescancausesynapticdysfunction [34],andthere isevidence
thatpathologicaltaureducesnetworkactivity[35].Suchareduc-
tion is well compatiblewith the reduction of a novelty response
in the hippocampus and amygdala as observed in our study.
Although CSF total tau and CSF p-tau are known to be
highly correlated, they are considered to reflect different path-
ological processes because they behave differently in other
diseases. For instance, unlike total tau, p-tau is not elevated
in Creutzfeldt-Jakob disease despite the presence of massive
neurodegeneration [36]. Hence, in the current research frame-
work, p-tau is not considered to be a marker of neurodegener-
ation [12]. In our study, p-tau did not correlate with the
hippocampal novelty response. Furthermore, a correlation
with recognition memory performance was only marginal.
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are neurotoxic and cause synaptic dysfunction [1,13,37]. A
recent study indicated that the earliest accumulation of Ab
oligomers (evident in decreased Ab42 levels in CSF but no
discernible amyloid plaque deposition with PET) reduces
the resting-state connectivity of the precuneus [29]. We
did not observe a relationship between Ab42 levels and nov-
elty responses in any brain region. Although it is possible
that resting-state connectivity is more sensitive to Ab42 pa-
thology than the novelty responses, our data indicate that
the previously reported [29] connectivity decrease is not
likely to be accompanied by decreased memory encoding
for novel events. We also observed that the impact CSF total
tau on hippocampal/amygdala novelty responses was inde-
pendent of Ab42 levels. Indeed, histological studies have
noted that early tau pathology has little overlap with Ab ag-
gregation [38,39]. Likewise, PET studies showed that
amyloid pathology is more ubiquitous in the cortex and
shows a preponderance in parietal cortical regions and
midline posterior regions including the precuneus [29,40]
rather than medial temporal lobe regions.
This study has a number of limitations. Our sample size
was not large enough to conduct analyses within each sub-
group or within early and late stages of the Alzheimer’s
spectrum separately. Furthermore, this was a cross-
sectional analysis, and longitudinal data would be helpful
to be able to relate synaptic dysfunction to the rate of neuro-
degeneration as derived from atrophy over time. These ex-
tensions would also help to further clarify the dissociation
between total tau and p-tau. Finally, although we spend
considerable effort to achieve high imaging quality (harmo-
nized standard operating procedures across sites, continuous
QA of data quality and participant positioning, estimation of
volumes using combined analyses of T1 and bespoke T2 im-
ages), it is possible that total tau levels were associated with
subtle atrophy of the neuropil that we have not been able to
capture at 3T. It would be valuable to follow-up on our re-
sults using ultrahigh-resolution imaging at 7T.
To summarize, our results indicate that tau pathology can
reduce novelty processing in the core brain regions where it
originates irrespective of Ab42 and irrespective of local
gross structural integrity. The independence of synaptic
dysfunction potentially caused by tau pathology indicate
that regional novelty responses may be used as functional
indices of target engagement in proof-of-concept studies tar-
geting tau-related neurotoxicity. Treatment failures with
disease-modifying drugs in clinically manifest AD have
highlighted that a need to initiate interventions before irre-
versible neurodegeneration, or atrophy, has occurred [41].
This requires the characterization of the earliest abnormal-
ities of synaptic function rather than atrophy in the preclin-
ical phase of AD [42]. Our data need to be confirmed in a
larger sample, but they raise the possibility that tau may
cause synaptic dysfunction irrespective of local atrophy
and therefore suggest that in the early stages of the AD spec-
trum dysfunction caused by tau might be partly reversible.Acknowledgments
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manuscript.RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources and
meeting abstracts and presentations. Cerebrospinal
fluid (CSF) total tau levels are viewed to reflect neu-
rodegeneration. However, there is also recent evi-
dence that intact neurons may contribute to these
CSF levels and that tau may be associated with syn-
aptic dysfunction. These relevant studies are appro-
priately cited.
2. Interpretation: Our findings indicate a relationship
between CSF total tau levels and brain dysfunction.
This hypothesis is discussed in relation to the prevail-
ing view that they are primarily related to neurode-
generation.
3. Future directions: The manuscript proposes that the
assessment of the brain function with task–
functional magnetic resonance imaging, in conjunc-
tion with measures of brain volume and CSF
biomarkers, may yield valuable insights into our
understanding of how biomarkers are related to
behavioral impairment. Larger samples are needed to
further advance this topic.
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